Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00197301
Status:
COMPLETED
Last Update Posted:
2006-11-07
First Post:
2005-09-12
Brief Title:
Liposomal Based Intranasal Influenza VaccineSafety and Efficacy
Sponsor:
Hadassah Medical Organization
Organization:
Hadassah Medical Organization
Study Overview
Official Title:
Phase 1 Study to Examine the Safety and Efficacy of a Novel Liposomal Based Intranasal Influenza Vaccine
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Influnza vaccination is highly recommended over the age of 50but is only 50 efficatious among the elderly A Vaccine given as a nasal spray may improve compliance and local immunityLiposomes are lipid particles that may serve as carriers for the vaccine and together they enhance the local immune response in mice when given as nasal sprayThis study aims to examine the safety and nasal and humoral responses to the nasal vaccine compared to the commercial muscular vaccine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None